Atul Chugh, MD
Cardiovascular Disease · Indianapolis, INNPI 1447463864
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Amarin Pharma, Inc. at 33.7% of the total. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $620.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$82K
- Medtronic$78K
- Boston Scientific$42K
- Angiodynamics, Inc.$20K
- Biostable Science & Engineering$10K
- Idorsia Pharmaceuticals US Inc$5K
- plus $5K from 24 others
Across 51 payments — averaging $10,446 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$358K
- Merck$118K
- Regeneron$37K
- Angiodynamics, Inc.$20K
What the payments were for
- Consulting fees$64,70327%
- Speaking & faculty fees$144,41360%
- Travel & lodging$21,4599%
- Food & beverage$11,3155%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 78 | $81,538 |
| Medtronic | 141 | $77,601 |
| Boston Scientific | 63 | $41,926 |
| Angiodynamics, Inc. | 8 | $20,475 |
| Biostable Science & Engineering | 6 | $9,952 |
| Idorsia Pharmaceuticals US Inc | 5 | $5,097 |
| Novartis | 25 | $2,276 |
| Edwards Lifesciences | 8 | $1,082 |
| Cvrx, Inc. | 2 | $302 |
| Heartflow, Inc. | 3 | $216 |
| Pfizer | 10 | $163 |
| E.r. Squibb & Sons, L.L.C. | 5 | $163 |
| Abiomed | 1 | $152 |
| Johnson & Johnson | 3 | $151 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $139 |
| Boehringer Ingelheim | 2 | $132 |
| Lexicon Pharmaceuticals, Inc. | 1 | $126 |
| AstraZeneca | 6 | $95 |
| Novo Nordisk | 4 | $78 |
| Abbott | 2 | $46 |
| Philips North America LLC | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Merck | 3 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Shockwave Medical, Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
| Elutia, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$80,129
- SYMPLICITY G3$43,408
- Watchman$21,777
- AngioVac$19,729
- WATCHMAN Access System$18,281
- Tryvio$5,033
- RESOLUTE ONYX$2,047
- ENTRESTO$1,874
- Barostim Neo System$302
- FFRct$163
- Impella$152
- Inpefa$126
- XARELTO$125
- JARDIANCE$119
- CAMZYOS$110
- WATCHMAN FLX$109
How this compares
$241,903 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $238,935 |
| EntrestoSacubitril/Valsartan | 185 | $237,165 |
| JardianceEmpagliflozin | 65 | $78,451 |
| VerquvoVericiguat | 22 | $33,380 |
| XareltoRivaroxaban | 22 | $27,218 |
| VascepaIcosapent Ethyl | 29 | $21,183 |
| Repatha SureclickEvolocumab | 18 | $18,716 |
| Praluent PenAlirocumab | 11 | $12,830 |
| FarxigaDapagliflozin Propanediol | 11 | $11,619 |
| Metoprolol Succinate | 329 | $4,193 |
| Ezetimibe | 197 | $4,187 |
| Atorvastatin Calcium | 376 | $3,383 |
| Carvedilol | 428 | $3,182 |
| Eplerenone | 28 | $2,650 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 84 | $2,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $238,935181 claims |
| NovartisEntresto | $2,276 | $237,165185 claims |
| Boehringer IngelheimJardiance | $132 | $78,45165 claims |
| MerckVerquvo | $30 | $33,38022 claims |
| Johnson & JohnsonXarelto | $151 | $27,21822 claims |
| AstraZenecaFarxiga | $95 | $11,61911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.